USANA Health Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Schedule II - Valuation and Qualifying Accounts

Schedule II - Valuation and Qualifying Accounts

12 Months Ended

Jan. 01, 2022

Notes to Financial Statements

SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS

(in thousands)

Description		*Balance at beginning of period*				*Charged to costs and expenses*				*Deductions*				*Balance at end of period*

January 1, 2022
Allowance for sales returns		$	819			$	7,213			$	7,485			$	547
Allowance for doubtful accounts		$	372			$	148			$	16			$	504
Valuation allowance - deferred tax assets		$	81,401			$	18,557			$	-			$	99,958

January 2, 2021
Allowance for sales returns		$	772			$	115			$	68			$	819
Allowance for doubtful accounts		$	261			$	131			$	20			$	372
Valuation allowance - deferred tax assets		$	64,285			$	17,116			$	-			$	81,401

December 28, 2019
Allowance for sales returns		$	839			$	168			$	235			$	772
Allowance for doubtful accounts		$	139			$	146			$	24			$	261
Valuation allowance - deferred tax assets		$	44,199			$	20,086			$	-			$	64,285